Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00768482 · ClinicalTrials.gov registry record · Phase 3
A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence
A Phase 3 study, sponsored by Titan Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 9
- Enrollment target
NCT00768482 is a Phase 3 study that was terminated before completion, run by Titan Pharmaceuticals. The registered enrollment target is 9 participants.
The verdict
NCT00768482, a Phase 3 study, was terminated before completion, sponsored by Titan Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study will measure the amount of buprenorphine found in the blood after taking sublingual buprenorphine tablets versus after implantation with 4 Probuphine (buprenorphine implants).
Interventions
- DRUG Probuphine (buprenorphine implant)
- DRUG Sublingual Buprenorphine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-09 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00768482
The ClinicalTrials.gov registry entry for NCT00768482 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Titan Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Probuphine (buprenorphine implant) is the first listed.
NCT00768482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00768482 about?
NCT00768482 is a clinical study titled "A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence". This study will measure the amount of buprenorphine found in the blood after taking sublingual buprenorphine tablets versus after implantation with 4 Probuphine (buprenorphine implants).
What is the current status of trial NCT00768482?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 9 participants. The study started on 2008-09. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00768482?
The interventions under investigation include: Probuphine (buprenorphine implant) (DRUG), Sublingual Buprenorphine (DRUG).
Who is sponsoring clinical trial NCT00768482?
This trial is sponsored by Titan Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.